The present invention discloses a method of determining the presence of autoimmune disease with the use of glycan biomarkers. A method of improving the detection sensitivity of trace glycans from a mixture of glycans and a microfluidic chip therefor are also disclosed.

The invention belongs to the technical field of natural medicinal chemistry and quality control thereof, and relates to a method for determining the weight average molecular weight and the purity of a soluble salt of an acidic saccharide. The method comprises using metal ion content in the soluble salt of an acidic saccharide to correct the weight average molecular weight and the content of the of acid saccharide obtained by the combined use of the molecular sieve chromatography and a multi-angle laser scattering detector SEC-MALS. The method of the present invention can be used to more quickly and accurately determine the weight average molecular weight and content of acidic saccharide soluble salts.

The invention belongs to the technical field of natural medicinal chemistry and quality control thereof, and relates to a method for determining the weight average molecular weight and the purity of a soluble salt of an acidic saccharide. The method comprises using metal ion content in the soluble salt of an acidic saccharide to correct the weight average molecular weight and the content of the of acid saccharide obtained by the combined use of the molecular sieve chromatography and a multi-angle laser scattering detector SEC-MALS. The method of the present invention can be used to more quickly and accurately determine the weight average molecular weight and content of acidic saccharide soluble salts.

A chromatography column for the use of separation of acidic sugar chains, wherein the column comprises a first column and a second column, the second column connected by a flow path downstream of an outlet of the first column, and selected from the following (1) or (2): (1) the carrier of the first column is hydrophobically modified silica having a group containing a primary amine, a secondary amine or/and a tertiary amine, and the carrier of the second column is a resin having a group containing a primary amine, a secondary amine or/and a tertiary amine; (2) the carrier of the first column is a resin having a group containing a primary amine, a secondary amine or/and a tertiary amine, and the carrier of the second column is hydrophobically modified silica having a group containing a primary amine, a secondary amine, or/and a tertiary amine.

Provided is a method of detecting free mannose and glucose in serum using high performance liquid chromatography. Compared to existing technology, the pretreatment process of samples is simpler, the detection time is shortened, and the detection efficiency is greater. When detection of serum samples is carried out, mannose, rhamnose and glucose may be completely separated, and mannose and glucose will not affect each other during quantification, thereby ensuring the accuracy of detection results.

The claimed invention provides real-time and subsequent analysis personalized user based health, wellness and pharmaceutical and illicit drug detection information. Non-invasive techniques utilize saliva for body levels of wellness indicators and pharmaceutical and illicit drug ingestion which are coordinated over time. Saliva captured on sample strips are real-time indicator reviewed and subsequently analyzed using traditional analytical chemistry techniques including liquid chromatography/mass spectrometry (LC/MS) and coordinated with time of administration with optional genetic sequence analysis to confirm related disease conditions. By using P4 (Participatory, Personalized, Predictive, and Preventive) health management techniques the patient determines if the pharmaceutical is having the correct and desired effect for maximum therapeutic benefit. While illustrative embodiments detecting Metformin and Keppra are provided the system has broad pharmaceutical and illicit drug monitoring applicability.

Systems and methods that facilitate the automatic (or substantially automatic) preparation of a sample of a product containing polypeptides for glycan analysis and automatic (or substantially automatic) performance of a glycan assay of that sample. Thus, the preparation and analysis can be performed substantially in-real time, or, in other words, much more quickly than presently allowed by conventional systems and methods.

The present invention relates to a method for quantifying 3,6-anhydro-L-galactose using high-performance liquid chromatography and a differential refractometric index detector, whereby L-AHG and D-galactose, which are saccharification products of agarose or agar, can be independently quantified by controlling the separation conditions of the high-performance liquid chromatography/differential refractive index detector, even though the two materials are difficult to separate due to having similar molecular weights and structures.

A purification agent which includes a compound having a betaine structure, and which is for a sugar chain having a length equal to or longer than that of a monosaccharide or for a glycopeptide having a sugar chain having a length equal to or longer than that of a monosaccharide.

Provided is a method for determining, in a sample, enrichments of a first and a second stable-labeled tracer of a target substance including glucose, the first tracer and the second tracer having the same or similar chemical structure as the target substance, the method including: ionizing the first tracer, the second tracer and the target substance of the sample; measuring intensities of ions deriving from the target substance, the first tracer and the second tracer using a mass analyzer; calculating an enrichment of the first tracer from a first ratio of intensity of the ions deriving from the first tracer to the intensity of the ions deriving from the target substance employing a first calibration curve independent of enrichments of each of the second tracer; wherein the mass analyzer is operated so as to resolve an ion peak deriving from a tracer and having a width (m/z) at half maximum peak height equal to or smaller than 110.sup.2.